Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

EHA 2018

ALL

View all
1:11
Incorporating novel therapies into frontline ALL treatment
Oliver Ottmann • 14 Jun 2018
1:12
Promising outlook for frontline blinatumomab in Ph+ ALL
Giovanni Martinelli • 14 Jun 2018

CLL

View all
0:58
Ibrutinib for CLL within a population-based setting: a promising outlook
Lina van der Straten • 14 Jun 2018
1:54
Does TP53-mutated clonal size impact outcomes of CLL patients from the MURANO study?
Arnon Kater • 14 Jun 2018

CML

View all
1:53
DESTINY: achieving TFR by de-escalating therapy in CML
Richard Clark • 14 Jun 2018
2:10
The importance of achieving early molecular response in CML
Timothy Hughes • 14 Jun 2018

MM

View all
2:34
Early MRD negativity predicts depth of response to CAR T-cells in R/R MM
Nikhil Munshi • 14 Jun 2018
1:22
Promising outlooks for venetoclax combinations for MM
Shaji Kumar • 14 Jun 2018

Lymphoma

View all
3:27
Venetoclax: an unmet need in R/R mantle cell lymphoma after BTK inhibitors
Toby Eyre • 14 Jun 2018
2:18
Novel drug combinations for Hodgkin lymphoma: more effective & less toxic
Anna Sureda • 14 Jun 2018

MPNs

View all
3:17
Treatment challenges in myelofibrosis
Claire Harrison • 14 Jun 2018
2:06
Targeting CD123 to treat myelofibrosis and CMML
Naveen Pemmaraju • 14 Jun 2018

Clinical Practice

View all
2:20
Do results obtained in clinical trials translate accurately in real world practice?
Paul Richardson • 14 Jun 2018
2:06
Genetic profiling for high-risk MM is practical in a short timeframe
Matthew Jenner • 14 Jun 2018

Clinical Trial Updates

View all
2:23
FORTE: effective treatment of newly diagnosed MM with KRd
Francesca Gay • 14 Jun 2018
4:29
Multiple Myeloma trial highlights: ARROW, OPTIMISMM & ALCYONE
Mohamad Mohty • 14 Jun 2018
The content of VJHemOnc is intended for healthcare professionals